Ingenix, a Polish startup, is using generative AI to simulate clinical trials, aiming to cut drug development costs and timelines. This innovation addresses the pharmaceutical industry’s 90% failure rate for experimental drugs, despite $50 billion in annual investments. Ingenix’s platform predicts outcomes and side effects using multimodal biological data. The solution was supported by the International Finance Corporation (IFC) with the aim of scaling in emerging markets. Hence, increasing access to essential medicines. Considering the high promise, there is still the ethical consideration of these data biases and representativeness. Especially in underserved areas, which may affect the equity and efficiency of such medical innovations that are powered by AI.
AI Simulation Technology Enhances Drug Trial Efficiency
The platform of Ingenix has a generative AI co-pilot that models clinical trials at the molecular, cellular, and population levels. It incorporates various biological feeds, genomics, proteomics, imaging, and phenotypic data in its estimations of trial end points and adverse events. With the help of this model, the preclinical and clinical decision-making process gets quicker. Physical trials are less relied upon. As an example, the AI will be able to run molecular docking and protein interaction simulations. On a scale and in time durations that the traditional models cannot reproduce.
Chaining of thought, time series processing, 3D structures, and medical imaging are also some of the techniques adopted by the technology. This enables it to predict probable consequences and detect toxic effects at an earlier stage. Make the necessary proactive amendments in drug development practices on a real-time basis. This innovation has the potential to open drug development to patients with rare diseases or neglected diseases in general. As much can be achieved in terms of time and cost savings. Simulation would enable pharmaceutical companies to speedily test the efficacy and safety of drugs instead of years of trial and error. Working up to the time when large-scale experiments are conducted on human subjects.
IFC Support Signals Push for Equitable Health Access
Ingenix has raised a $9 million seed funding round that was provided by the International Finance Corporation (IFC) and the World Bank Group. The strategic investment is an indication of how much interest there is in advancing the use of AI in hastening health equity around the world. Ingenix’s simulation platform has the potential to change that because the high cost of drug development in the past has favored innovation in more affluent markets.
The presence of IFC not only indicates that the venture is not solely profit-seeking. But it also implies the creation of a sustainable supply infrastructure in the biotechnology sector within growing economies, which is easily accessible. The technology has the potential to drop the barrier to entry for regional pharmaceutical manufacturing companies. Since AI can minimize the expenses of a trial. Enable local manufacturers to create drugs that meet regional needs and disease load profiles.
This investment is also geared towards the support of global health, which is intended to build health systems using digital and AI tools. Aggregating the results of clinical trials on regionally applicable scenarios, the countries might not need to rely on the implemented western-approved drugs, which do not meet local genetic and environmental conditions.
Ethical Risks of Data Bias in Simulated Clinical Trials
Although the benefits are promising, the AI platform developed by Ingenix is endangered by serious ethical issues. The first of which is data bias. The quality of its simulations is limited by the quality and diversity of datasets. Both of which are out of reach in developing countries. The models might be biased towards Western populations. So when they are deployed to other parts of the world, their results can be inaccurate or even disastrous. Training data should also be representative, since it is a vital measure toward not perpetuating health disparities.
About The Author
